Navigation Links
Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
Date:11/16/2007

- Republic of Georgia Drug Agency Approves Protocol for New Clinical Trial

of Bavituximab in Combination with Docetaxel -

TUSTIN, Calif., Nov. 16 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced that its Phase II clinical protocol to study bavituximab in combination with the chemotherapy drug docetaxel in patients with metastatic breast cancer has been approved by the Drug Agency of the Ministry of Labour, Health and Social Affairs of Georgia. The open label, multi-center safety and efficacy trial is expected to begin enrolling patients by early 2008.

The primary objective of the trial is to assess the overall response rate to the combination of bavituximab with docetaxel, a chemotherapy drug commonly used in the treatment of metastatic breast cancer. Secondary objectives include measuring time to tumor progression, duration of response, overall patient survival and safety parameters. In the trial's two-stage design, up to 15 patients with metastatic breast cancer will be enrolled initially. The study will then be expanded up to a total of 46 patients if promising results are observed. The trial is expected to enroll patients at a minimum of three clinical trial sites.

"We are eager to assess bavituximab's potential in Phase II combination studies in a number of cancer indications, and we are very pleased to have received prompt regulatory approval to proceed with this breast cancer trial," said Steven W. King, president and CEO of Peregrine. "The clinical sites in the Republic of Georgia that will be par
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2009)...- Welcome to syngo® .plaza(1), the ne...rom Siemens Healthcare. As the first Picture A...iemens where 2D, 3D, and 4D reading come together ...e the way multimodality images are read today. Sie...ientific Assembly and Annual Meeting of the Radiol...
(Date:11/27/2009)...ire-FirstCall/ -- GSI Group Inc. (Pink Sheets: GSI...logy products and semiconductor systems, today ann...reholders has been scheduled for Friday, April 30,...be announced in due course. As previously announc... Stephen Bershad, a holder of greater than ten per...
(Date:11/27/2009)...ire-USNewswire/ -- Preventing disease is the goal ...y year, new vaccines are being added to assist in ...nity for the same period of time? And, if not, whe...munity strong? ,, In this month,s issue of Pe...ediatrics, Michael Pichichero MD, Director of the ...
(Date:11/27/2009)... economic burdens, study predicts , , FR...ople with diabetes in the United States is expecte...edicts. , That would bring the total by 2034 to...om 23.7 million today. , , At the same time, the..., the study also warns, rising from an estimated $...
(Date:11/27/2009)...ve anatomy education apps from Modality and Lippin... learning opportunities for iPhone and iPod touch ...mber 27, 2009 -- Modality, Inc. and Lippincott W... Kluwer Health, today announced the availability o...e. Clemente’s Anatomy, Rohen’s Photogr...
Breaking Medicine News(10 mins):Health News:Siemens Healthcare Unveils syngo.plaza at RSNA 2009 2Health News:Siemens Healthcare Unveils syngo.plaza at RSNA 2009 3Health News:GSI Group Calls Shareholders Meeting 2Health News:Why Some Vaccines May Require A Booster 2Health News:Why Some Vaccines May Require A Booster 3Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 2Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 3Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 4Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 5
...and MILPITAS, Calif., Sept. 27 ,Flextronics Intern...ation,(NYSE: SLR ) today announced that Flextroni...proved the completion of Flextronics,s proposed,ac...as of June 4, 2007. Flextronics shareholders, at t...
...3,000 leading scientists and clinicians to present...., Sept. 27 - An international,medical meeting wil...m all,fields of science and medicine to Anaheim Oc...sis Conference is an annual,ritual for leading CF ...
...Sept. 27 Bristol-Myers Squibb,(NYSE: BMY ) annou...mpany,s,Research and Development organization as s... and Licensing. He will report to Dr. Elliott Siga...for Bristol-Myers Squibb, as we look to further bu...
...s leading cause of parasitic infections in U.S. , ...have sequenced the genome of the intestinal parasi...,000 reported infections a year in the United Stat...Giardia through contact with infected stool or by ...
...ER, Mass. Several recent research studies publishe...adolescents who see smoking scenes in movies are m...h, public health groups have called for Restricted...ot have the intended effect of putting such movies...
... Real Estate Services Firm Assembles Veteran Healt...dership, CHICAGO, Sept. 27 Alter+Care, one of th...nt firms, has established an,Advisory Board to pro..., announced the Alter+Care Advisory Board,s format...
Other Medicine News:Health News:Flextronics Shareholders and Solectron Stockholders Approve Acquisition 2Health News:Flextronics Shareholders and Solectron Stockholders Approve Acquisition 3Health News:Anaheim to Host World's Largest Cystic Fibrosis Medical Meeting 2Health News:Jeremy Levin Joins Bristol-Myers Squibb as Senior Vice President of External Science, Technology and Licensing 2Health News:Scientists Map Intestinal Bug's Genome 2Health News:R rating might be unlikely to affect teens exposure to smoking in movies 2Health News:Alter+Care Creates the Advisory Board 2Health News:Alter+Care Creates the Advisory Board 3
(Date:11/25/2009)... , EXTON, Pa., Nov. 25 BioTren...aunchTrends(TM) : Stelara report, the first i... tracking the launch of Centocor Ortho-Biotech,s S...months of availability. Each wave of the report p...rmatologists and qualitative information from a su...
(Date:11/25/2009)... , BASKING RIDGE, N.J., Nov. 25 /PRNewswire/ -...ding the development of antithrombotic aptamers wi...zo, PhD, CEO and President, will be presenting at ...ce at the New York Palace Hotel in New York City. ...(EST) on Tuesday, December 1 and will include an o...
(Date:11/25/2009)... , EAST BRUNSWICK, N.J., Nov. 25 /PRNewswire...cturer of direct digital Radiography ( ddR ) syste...acquired by a private Swiss Investor with a long t...g brand. The acquisition included all assets and i...entory. After 25 years of success and growth Swiss...
Breaking Medicine Technology:Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High 2Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009 2Swissray International Announces New Ownership 2Obesity Contributes to Rapid Cartilage Loss 51575 1Obesity Contributes to Rapid Cartilage Loss 51575 2Obesity Contributes to Rapid Cartilage Loss 51575 3Obesity Contributes to Rapid Cartilage Loss 51575 4Elbit Imaging Ltd Announces Swiss Team Uses InSightecs ExAblate 28R 29 4000 Brain System to Treat Patients With Functional Brain Disorders 4721 1Elbit Imaging Ltd Announces Swiss Team Uses InSightecs ExAblate 28R 29 4000 Brain System to Treat Patients With Functional Brain Disorders 4721 2Elbit Imaging Ltd Announces Swiss Team Uses InSightecs ExAblate 28R 29 4000 Brain System to Treat Patients With Functional Brain Disorders 4721 3Elbit Imaging Ltd Announces Swiss Team Uses InSightecs ExAblate 28R 29 4000 Brain System to Treat Patients With Functional Brain Disorders 4721 4Simulating medical situations helps students learn retain basic science concepts 51568 1Simulating medical situations helps students learn retain basic science concepts 51568 2
...Shows ADHD Patch Provides Tolerable and Effective ... SHP, Nasdaq:,SHPGY, TSX: SHQ), the global special...from a 12-month study of DAYTRANA(TM) (methylpheni...peractivity Disorder (ADHD),patch, demonstrated th...,and symptom control improvement in children aged ...
...umor Activity of NKTR-102 Associated With Increase... Active Metabolite of Irinotecan, SAN FRANCISCO, ...ented positive preclinical data today on its propr... at the AACR-NCI-EORTC,International Conference in...lighted the anti-tumor activity and unique pharmac...
Other Medicine Technology:Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system) 2Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system) 3Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system) 4Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system) 5NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models 2NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models 3NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models 4NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models 5
...nal reference laboratory and a worldwide leader in...RUP offers an extensive test menu of highly comple...c pathology. Owned by the University of Utah, ARUP...he nation's university teaching hospitals and chil...
...nal reference laboratory and a worldwide leader in...RUP offers an extensive test menu of highly comple...c pathology. Owned by the University of Utah, ARUP...he nation's university teaching hospitals and chil...
...nal reference laboratory and a worldwide leader in...RUP offers an extensive test menu of highly comple...c pathology. Owned by the University of Utah, ARUP...he nation's university teaching hospitals and chil...
...nal reference laboratory and a worldwide leader in...RUP offers an extensive test menu of highly comple...c pathology. Owned by the University of Utah, ARUP...he nation's university teaching hospitals and chil...
Medicine Products: